News

Traws Pharma Posts Q2 Revenue Jump

Cash and equivalents (GAAP) totaled $13.1 million as of Q2 2025. These 10 stocks could mint the next wave of millionaires › Traws Pharma (NASDAQ:TRAW), a clinical-stage biopharmaceutical company ...
The Manila Times47m

Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ('Adial” or the 'Company”), a clinical-stage biopharmaceutical company focused on ...